Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0289

Sigma-Aldrich

Bromfenac sodium

≥98% (HPLC)

Synonym(s):

2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H11BrNNaO3
CAS Number:
91714-93-1
Molecular Weight:
356.15
MDL number:
MFCD03701673
UNSPSC Code:
12352200
PubChem Substance ID:
329825297
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

faintly yellow to dark yellow

solubility

H2O: ≥5 mg/mL

storage temp.

2-8°C

SMILES string

[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2

InChI

1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1

InChI key

HZFGMQJYAFHESD-UHFFFAOYSA-M

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

Application

Bromfenac sodium has been used:
  • to study its ability to bind to melanin
  • in the synthesis of bromfenac indolinone standard
  • to analyze its permeability in porcine conjunctiva

Biochem/physiol Actions

Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID); COX1 and COX2 inhibitor; opthalmic analgesic.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000365928
0000303379
0000303379
0000365928
0000375431

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Dexamethasone powder, BioReagent, suitable for cell culture, ≥97%

Sigma-Aldrich

D4902

Dexamethasone

Eiichi Uchio et al.
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 221(3), 153-158 (2007-04-19)
We evaluated the efficacy and safety of long-term management of patients with vernal keratoconjunctivitis (VKC) with bromfenac sodium eye drops in combination with corticosteroids and anti-allergic eye drops. Twenty-two patients with VKC were randomly assigned to receive two test eye
Thomas R Walters et al.
Ophthalmology, 121(1), 25-33 (2013-09-12)
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.07% (Prolensa) dosed once daily for the treatment of ocular inflammation and pain in subjects who underwent cataract surgery with posterior chamber intraocular lens implantation. Two phase 3, randomized
Steven M Silverstein et al.
Current medical research and opinion, 27(9), 1693-1703 (2011-07-15)
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% dosed once daily for the treatment of ocular inflammation and pain following cataract extraction with posterior chamber intraocular lens implantation. A total of 455 subjects (455 study eyes:
Naoko Endo et al.
Acta ophthalmologica, 88(8), 896-900 (2009-09-04)
To compare the efficacy of bromfenac sodium ophthalmic solution (BF) and a steroidal solution (ST) administered prophylactically against cystoid macular oedema and anterior-chamber inflammation after phacoemulsification and intraocular lens implantation and to assess macular thickness changes using optical coherence tomography
James P Driscoll et al.
Chemical research in toxicology, 31(4), 223-230 (2018-03-24)
Bromfenac is a nonsteroidal anti-inflammatory drug that was approved in the United States in 1997. It was withdrawn from clinical use less than one year later, in 1998, due to hepatotoxicity. We investigate the potential of bromfenac to be metabolized
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service